Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease

被引:2
|
作者
Blacher, J [1 ]
Demuth, K [1 ]
Guerin, AP [1 ]
Vadez, C [1 ]
Moatti, N [1 ]
Safar, ME [1 ]
London, GM [1 ]
机构
[1] APHP, Broussais Hosp, INSERM, U337,Dept Internal Med, Paris, France
关键词
homocysteine; cardiac mass; uremia; hemodialysis; cardiovascular risk;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In patients with end-stage renal disease, plasma homocysteine and cardiac mass are both increased and considered independent risk predictors for cardiovascular-specific morbidity and mortality. In order to establish a relationship between these two parameters, we determined cardiac mass and plasma homocysteine in 75 patients with end-stage renal disease undergoing chronic hemodialysis. We observed a statistically significant positive association between plasma homocysteine and cardiac mass index or either of its components. This was observed even after adjustment for age, sex, systolic blood pressure and hematocrit (p = 0.0027). The adjusted odds ratio for left ventricular hypertrophy was 6.6 (95 % confidence interval 1.3-32.8) for subjects with the highest versus the lowest plasma homocysteine concentrations. This cross-sectional study is the first to show a statistical link between plasma homocysteine and cardiac structure, independently of mechanical factors. High plasma homocysteine concentrations are associated with an increased adjusted risk of left ventricular hypertrophy in end-stage renal disease patients.
引用
收藏
页码:248 / 255
页数:8
相关论文
共 50 条
  • [1] Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease
    Blacher, J
    Demuth, K
    Guerin, A
    Vadez, C
    Moatti, N
    Safar, M
    London, G
    [J]. JOURNAL OF HYPERTENSION, 1998, 16 : S12 - S12
  • [2] Plasma reduced homocysteine concentrations are increased in end-stage renal disease
    Hoffer, LJ
    Robitaille, L
    Elian, KM
    Bank, I
    Hongsprabhas, P
    Mamer, OA
    [J]. KIDNEY INTERNATIONAL, 2001, 59 (01) : 372 - 377
  • [3] Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients
    Skoupy, S
    Födinger, M
    Veitl, M
    Perschl, A
    Puttinger, H
    Röhrer, C
    Schindler, K
    Vychytil, A
    Hörl, WH
    Sunder-Plassmann, G
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (05): : 1331 - 1337
  • [4] Comparative effects of hydroxocobalamin and cyanocobalamin on plasma homocysteine concentrations in end-stage renal disease
    Hoffer, LJ
    Djahangirian, O
    Bourgouin, PE
    Eid, J
    Saboohi, F
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (10): : 1362 - 1367
  • [5] Assessing plasma total homocysteine in patients with end-stage renal disease
    Urquhart, Bradley L.
    House, Andrew A.
    [J]. PERITONEAL DIALYSIS INTERNATIONAL, 2007, 27 (05): : 476 - 488
  • [6] Role of homocysteine in end-stage renal disease
    Wu, Chia-Chao
    Zheng, Cai-Mei
    Lin, Yuh-Feng
    Lo, Lan
    Liao, Min-Tser
    Lu, Kuo-Cheng
    [J]. CLINICAL BIOCHEMISTRY, 2012, 45 (16-17) : 1286 - 1294
  • [7] The role of homocysteine in end-stage renal disease
    Yeun, JY
    [J]. SEMINARS IN DIALYSIS, 1998, 11 (02) : 95 - 101
  • [8] Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease
    Buccianti, G
    Baragetti, I
    Bamonti, F
    Furiani, S
    Dorighet, V
    Patrosso, C
    [J]. JOURNAL OF NEPHROLOGY, 2004, 17 (03) : 405 - 410
  • [9] The Association Between Malignancy and End-stage Renal Disease in Taiwan
    Liang, Ji-An
    Sun, Li-Min
    Yeh, Jun-Jun
    Sung, Fung-Chang
    Chang, Shih-Ni
    Kao, Chia-Hung
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (06) : 752 - 757
  • [10] Plasma elimination of cardiac troponin I in end-stage renal disease
    Ellis, K
    Dreisbach, AW
    Lertora, JJL
    [J]. SOUTHERN MEDICAL JOURNAL, 2001, 94 (10) : 993 - 996